Phenylpiracetam and Trenbolone Interaction: Monitor | Peptide Database

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss. ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss. Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%). 91% achieved near-normal blood sugar levels versus 42% with placebo. ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%. Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

Join others researching Cardarine — share findings, ask questions, and learn from real experiences Cardarine (GW501516) is a synthetic PPAR-delta (peroxisome proliferator-activated receptor delta) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the early 2000s for the treatment of metabolic and cardiovascular diseases, including dyslipidemia, obesity, and diabetes. Despite being almost universally categorized alongside SARMs in the performance enhancement market, Cardarine is not a selective androgen receptor modulator and does not bind to the androgen receptor at all. Its mechanism is entirely distinct: it activates PPAR-delta, a nuclear receptor that regulates fatty acid oxidation, energy expenditure, and lipid metabolism. In preclinical studies, Cardarine demonstrated remarkable effects on endurance capacity, fat oxidation, and lipid profiles. However, development was abandoned by GSK in 2007 after preclinical toxicology studies in rodents revealed an increased incidence of tumors across multiple organ systems when the compound was administered at supratherapeutic doses over extended periods. This cancer signal remains the central controversy and safety concern surrounding Cardarine. The compound has never been approved for human use by any regulatory agency, and no clinical trials have been completed. It is classified as a prohibited substance by the World Anti-Doping Agency (WADA). Despite these concerns, Cardarine continues to be widely available through research chemical suppliers and is used in performance enhancement contexts for its potent endurance-boosting and fat-burning properties. Cardarine acts as a potent and highly selective agonist of PPAR-delta, a nuclear hormone receptor expressed in skeletal muscle, liver, adipose tissue, and the gastrointestinal tract. Upon binding to PPAR-delta, Cardarine triggers a conformational change that promotes heterodimerization with retinoid X receptor (RXR), and the resulting complex binds to PPAR response elements (PPREs) in the promoter regions of target genes. This transcriptional activation upregulates a suite of genes involved in fatty acid oxidation, mitochondrial biogenesis, and energy uncoupling. In skeletal muscle, PPAR-delta activation by Cardarine shifts the metabolic fuel preference from glucose toward fatty acids, dramatically increasing the rate of beta-oxidation. This metabolic reprogramming effectively transforms type II (fast-twitch, glycolytic) muscle fibers toward a more oxidative phenotype, similar to type I (slow-twitch) fibers, which underpins the compound's dramatic effects on endurance capacity. Preclinical studies in mice demonstrated that GW501516 treatment increased running endurance by up to 68% compared to controls. In the liver and adipose tissue, PPAR-delta activation by Cardarine promotes fatty acid catabolism and reduces lipogenesis, resulting in reduced body fat storage and improved lipid profiles (increased HDL, decreased LDL, reduced triglycerides). Critically, Cardarine does not interact with the androgen receptor, does not suppress the hypothalamic-pituitary-gonadal (HPG) axis, and does not affect endogenous testosterone production. This non-hormonal mechanism means it does not cause testosterone suppression and does not require post-cycle therapy.